Release Date: 25/06/19 09:35 Summary: IN SITU EXPANSION STUDY DELIVERS STRONG VALUE ADD POTENTIAL Price Sensitive: Yes Download Document 5.5MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%